| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc. | PN-235 (JNJ-77242113) - (FRONTIER 1) | Plaque psoriasis | Phase 2b | Data Released | Oral | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | PTG-100 | Ulcerative colitis | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| Protagonist Therapeutics Inc. | Rusfertide (PACIFIC) | Polycythemia Vera (PV) | Phase 2 | Data Released | Subcutaneous | Hematology |
| Protagonist Therapeutics Inc. | Rusfertide - (REVIVE) | Polycythemia vera | Phase 2 | Data Released | Subcutaneous | Hematology |
| Protagonist Therapeutics Inc. | Rusfertide (PTG-300) | Hereditary hemochromatosis | Phase 2 | Trial Planned | Subcutaneous | Genetic Disorder |
| Protagonist Therapeutics Inc. | PN-943 - (IDEAL) | Ulcerative colitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Protagonist Therapeutics Inc. | PTG-200 | Crohn's disease | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| Protagonist Therapeutics Inc. | Rusfertide (PTG-300) | Beta-thalassemia | Phase 2 | Trial Discontinued | Subcutaneous | Genetic Disorder |